Li et al. reported that the mTOR pathway activated by ketamine increases the levels of synaptic signaling proteins (synapsin I, PSD95, and GluR1) and increases the number and function of new synapses in the prefrontal cortex of rat models of depression [33]. Here, SYN1 is linked to depressive symptom measurement.